Compare HIPO & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIPO | KROS |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | 540 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 676.8M | 584.9M |
| IPO Year | N/A | 2020 |
| Metric | HIPO | KROS |
|---|---|---|
| Price | $27.26 | $11.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $38.67 | $22.25 |
| AVG Volume (30 Days) | 84.6K | ★ 411.6K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | N/A | ★ 2.30 |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | $27.32 | N/A |
| Revenue Next Year | $23.24 | $727.07 |
| P/E Ratio | $7.64 | ★ $4.84 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.92 | $10.42 |
| 52 Week High | $38.98 | $22.55 |
| Indicator | HIPO | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 56.89 | 42.72 |
| Support Level | $27.00 | $10.45 |
| Resistance Level | $31.92 | $16.12 |
| Average True Range (ATR) | 0.82 | 0.57 |
| MACD | 0.24 | 0.18 |
| Stochastic Oscillator | 97.65 | 44.84 |
Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.